SCHEMBL70799

SCHEMBL70799

CCCC1CCN(CC)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.43
HSD11B1 P28845 1/20 0.42
GNAO1 P09471 1/20 0.42
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
EPHX1 P07099 2/20 0.38
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD2 P14416 1/20 0.37
CHRM3 P20309 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
CYP1A2 P05177 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24757176 0.91 ACHE (0.44) HRH3SMN1; SMN2HSD11B1GNAO1CHRM5
SCHEMBL31273888 0.90 HRH3 (0.49) HRH3SMN1; SMN2HSD11B1GNAO1MAOA
SCHEMBL26329494 0.88 OPRL1 (0.48) HRH3SMN1; SMN2HSD11B1GNAO1CHRM4
SCHEMBL16154793 0.86 HRH3 (0.37) HRH3SMN1; SMN2HSD11B1GNAO1MAOA
SCHEMBL12112146 0.86 CYP1A2 (0.54) HRH3SMN1; SMN2HSD11B1GNAO1CHRM2
SCHEMBL31273045 0.85 HRH3 (0.46) HRH3SMN1; SMN2HSD11B1GNAO1MAOA
SCHEMBL28149564 0.85 HRH3 (0.46) HRH3SMN1; SMN2HSD11B1GNAO1MAOA
SCHEMBL19578855 0.84 GNAO1 (0.50) HRH3SMN1; SMN2HSD11B1GNAO1CHRM2
SCHEMBL25700795 0.84 GNAO1 (0.50) HRH3SMN1; SMN2HSD11B1GNAO1EPHX1
SCHEMBL7741719 0.83 GNAO1 (0.49) HRH3GNAO1EPHX1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340435-A1 BASE EDITING OF ANGPTL3 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE VERVE THERAPEUTICS, INC. 2023-10-26 US disclosed
US-20230340435-A1 BASE EDITING OF ANGPTL3 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE VERVE THERAPEUTICS, INC. 2023-10-26 US disclosed
WO-2023192578-A1 PROTEIN DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023104155-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF 标新生物医药科技(上海)有限公司 2023-06-15 WO disclosed
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
EP-3394030-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS MODERNATX INC (US) 2021-12-22 EP disclosed
US-11186565-B2 Aromatic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-30 US disclosed
US-20210236474-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS UNIV MICHIGAN REGENTS (US) 2021-08-05 US disclosed
WO-2020264490-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
US-10875864-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2020-12-29 US disclosed
US-20090163511-A1 Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same RIGEL PHARMACEUTICALS, INC. (US) 2009-06-25 US disclosed
US-20090143430-A1 ERYTHROPOIETIN PRODUCTION ACCELERATOR KOWA CO., LTD. (JP) 2009-06-04 US disclosed
US-20090105212-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) 2009-04-23 US disclosed
WO-2009033084-A1 PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-03-12 WO disclosed
US-7384952-B2 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-10 US disclosed
US-7384952-B2 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-10 US disclosed
EP-1857459-A2 Pyrazolopyrimidine compound and a process for preparing the same TANABE SEIYAKU CO., LTD. (JP) 2007-11-21 EP disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 US disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed
US-6743777-B1 TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP ELI LILLY AND COMPANY 2004-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11186565-B2 Aromatic compound GLP1R, GPR119, GPR39 HRH3 1348/4885SMN1; SMN2 1620/4885HSD11B1 836/4885
US-20210236474-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS KDM1A, KDM4A, KDM1B HRH3 194/4885SMN1; SMN2 1311/4885HSD11B1 3280/4885
US-10875864-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors PIM2, PIM1, PIM3 HRH3 2245/4885SMN1; SMN2 3207/4885HSD11B1 4189/4885
US-20230340435-A1 BASE EDITING OF ANGPTL3 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE LDLR, PCSK9, APOB HRH3 4128/4885SMN1; SMN2 1420/4885HSD11B1 1963/4885
US-20090163511-A1 Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same AK2, PRKAA1, PRKAA2 HRH3 2573/4885SMN1; SMN2 1309/4885HSD11B1 4299/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 HRH3 758/4885SMN1; SMN2 1840/4885HSD11B1 392/4885
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression HRH3, HRH1, HRH4 HRH3 1/4885SMN1; SMN2 4112/4885HSD11B1 3254/4885
US-20090143430-A1 ERYTHROPOIETIN PRODUCTION ACCELERATOR EPOR, GHRHR, ARL1 HRH3 425/4885SMN1; SMN2 1331/4885HSD11B1 1804/4885
US-20090105212-A1 NOVEL ADENINE COMPOUND XDH, ADORA1, NUDT1 HRH3 162/4885SMN1; SMN2 2258/4885HSD11B1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.